Company news from the 05/05/06 News Brief

Share this article:
Biovail and AstraZeneca have entered into an agreement in which Biovail’s specialty sales force will promote AstraZeneca’s Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. AstraZeneca will continue to manufacture and supply all quantities of Zoladex, according to a joint statement from the companies. Biovail’s 85-member specialty sales force currently promotes Zovirax Cream and Zovirax Ointment, topical anti-viral treatments for genital herpes and cold sores, to specialists and selected primary-care physicians in the US.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.